{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:14:04Z","timestamp":1781525644378,"version":"3.54.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>T-lymphoblastic lymphoma (T-LBL) is a highly aggressive neoplasm of lymphoblasts of T-cell origin. Although promising improvements have been recently achieved, one third of patients experience relapse or refractory T-LBL. Therefore, optimal strategies for identifying high-risk patients are urgently needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>In the present study, 75 newly diagnosed adult patients (aged \u226515 years) with T-LBL were identified and the predictive value of complete blood count (CBC) abnormalities, including lymphocyte-monocyte ratio (LMR), neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) on clinical outcomes, was analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Using the receiver operating characteristic curve to determine the best cutoff values based on survival, it was found that patients with T-LBL with LMR \u22642.8, NLR \u22653.3, and PLR \u2265200 had both inferior progression-free survival (PFS) and inferior overall survival (OS), in which the differences were much more remarkable in the international prognostic index score 0\u20132 subgroup. In the multivariable analysis, NLR \u22653.3 together with age &amp;gt;40 years and central nervous system (CNS) involvement were identified to be independently associated with shortened PFS, whereas PLR \u2265200 and CNS involvement were identified to be independent risk factors for OS. LMR, NLR, and PLR were integrated to generate a \u201cCBC score\u201d model, which well separated adult patients with T-LBL into three risk groups, and the 3-year OS was 84%, 53%, and 30% for low-, intermediate-, and high-risk patients, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Overall, a \u201cCBC score\u201d model was initially promoted for stratification in adult patients with T-LBL using simple, widely available, and easy to interpret parameters in the largest adult T-LBL cohort to date.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Optimal strategies for identifying high-risk patients with T-lymphoblastic lymphoma (T-LBL) are urgently needed. In the largest adult T-LBL cohort to date, simple, inexpensive, widely available parameters were applied and revealed that patients with lymphocyte-monocyte ratio (LMR) \u22642.8, neutrophil-lymphocyte ratio (NLR) \u22653.3, and platelet-lymphocyte ratio (PLR) \u2265200 had both inferior progression-free survival and inferior overall survival (OS), in which the differences were much more remarkable in the international prognostic index score 0\u20132 subgroup. LMR, NLR, and PLR were integrated to generate a \u201ccomplete blood count score\u201d model, in which the 3-year OS was 84%, 53%, and 30% for low-, intermediate-, and high-risk patients, respectively.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0789","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T18:05:30Z","timestamp":1554487530000},"page":"e1123-e1131","source":"Crossref","is-referenced-by-count":26,"title":["Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma"],"prefix":"10.1093","volume":"24","author":[{"given":"Xiaoyan","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenchang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"2021122508043210200_onco12921-bib-0001","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","article-title":"Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia","volume":"99","author":"Hoelzer","year":"2002","journal-title":"Blood"},{"key":"2021122508043210200_onco12921-bib-0002","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: A high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"2021122508043210200_onco12921-bib-0003","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122508043210200_onco12921-bib-0004","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122508043210200_onco12921-bib-0005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.mayocp.2015.03.025","article-title":"Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis hodgkin lymphoma: Evaluation based on data from 1450 patients","volume":"90","author":"Tadmor","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"2021122508043210200_onco12921-bib-0006","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/bjc.2014.163","article-title":"The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients","volume":"110","author":"Krenn-Pilko","year":"2014","journal-title":"Br J Cancer"},{"key":"2021122508043210200_onco12921-bib-0007","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1479-5876-10-33","article-title":"Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes","volume":"10","author":"Milne","year":"2012","journal-title":"J Transl Med"},{"key":"2021122508043210200_onco12921-bib-0008","article-title":"Prognostic significance of systemic inflammation-based lymphocyte- monocyte ratio in patients with lung cancer: Based on a large cohort study","volume":"9","author":"Hu","year":"2014","journal-title":"PLoS One"},{"key":"2021122508043210200_onco12921-bib-0009","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ajh.23566","article-title":"The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy","volume":"88","author":"Rambaldi","year":"2013","journal-title":"Am J Hematol"},{"key":"2021122508043210200_onco12921-bib-0010","doi-asserted-by":"crossref","first-page":"32356","DOI":"10.18632\/oncotarget.16020","article-title":"Increased platelet-lymphocyte ratio closely relates to inferior clinical features and worse long-term survival in both resected and metastatic colorectal cancer: An updated systematic review and meta-analysis of 24 studies","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"2021122508043210200_onco12921-bib-0011","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00277-018-3276-y","article-title":"Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy","volume":"97","author":"Romano","year":"2018","journal-title":"Ann Hematol"},{"key":"2021122508043210200_onco12921-bib-0012","doi-asserted-by":"crossref","first-page":"18792","DOI":"10.18632\/oncotarget.13320","article-title":"Elevated neutrophil-to-lymphocyte ratio and monocyte-tolymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma","volume":"8","author":"Shi","year":"2017","journal-title":"Oncotarget"},{"key":"2021122508043210200_onco12921-bib-0013","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41598-018-19565-x","article-title":"Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers","volume":"8","author":"Dong","year":"2018","journal-title":"Sci Rep"},{"key":"2021122508043210200_onco12921-bib-0014","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12967-015-0409-0","article-title":"Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model","volume":"13","author":"Deng","year":"2015","journal-title":"J Transl Med"},{"key":"2021122508043210200_onco12921-bib-0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/10428194.2015.1045897","article-title":"The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified","volume":"57","author":"Beltran","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2021122508043210200_onco12921-bib-0016","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/2211-5463.12066","article-title":"Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: A systematic review and meta-analysis","volume":"6","author":"Xia","year":"2016","journal-title":"FEBS Open Bio"},{"key":"2021122508043210200_onco12921-bib-0017","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pbc.20550","article-title":"Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"47","author":"Raetz","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"2021122508043210200_onco12921-bib-0018","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.critrevonc.2017.03.020","article-title":"Lymphoblastic lymphoma","volume":"113","author":"Cortelazzo","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122508043210200_onco12921-bib-0019","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","article-title":"How I treat T-cell acute lymphoblastic leukemia in adults","volume":"126","author":"Litzow","year":"2015","journal-title":"Blood"},{"key":"2021122508043210200_onco12921-bib-0020","first-page":"416","article-title":"Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report","volume":"95","author":"Reiter","year":"2000","journal-title":"Blood"},{"key":"2021122508043210200_onco12921-bib-0021","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2001.19.11.2927","article-title":"High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation\/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group","volume":"19","author":"Sweetenham","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122508043210200_onco12921-bib-0022","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"2021122508043210200_onco12921-bib-0023","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1200\/JCO.1986.4.11.1628","article-title":"Treatment of lymphoblastic lymphoma in adults","volume":"4","author":"Coleman","year":"1986","journal-title":"J Clin Oncol"},{"key":"2021122508043210200_onco12921-bib-0024","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"2021122508043210200_onco12921-bib-0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pbc.21823","article-title":"Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR)","volume":"52","author":"Stark","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"2021122508043210200_onco12921-bib-0026","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2015.61.5385","article-title":"Pediatric-like acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: The GRAALL-LYSA LL03 Study","volume":"34","author":"Lepretre","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122508043210200_onco12921-bib-0027","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"2021122508043210200_onco12921-bib-0028","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122508043210200_onco12921-bib-0029","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"key":"2021122508043210200_onco12921-bib-0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: From mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"2021122508043210200_onco12921-bib-0031","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1158\/2326-6066.CIR-15-0313","article-title":"The complex role of neutrophils in tumor angiogenesis and metastasis","volume":"4","author":"Liang","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2021122508043210200_onco12921-bib-0032","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2014-08-531582","article-title":"Platelets at the interface of thrombosis, inflammation, and cancer","volume":"126","author":"Franco","year":"2015","journal-title":"Blood"},{"key":"2021122508043210200_onco12921-bib-0033","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/09537104.2018.1453059","article-title":"The pro-inflammatory role of platelets in cancer","volume":"29","author":"Olsson","year":"2018","journal-title":"Platelets"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0789","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0789","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1123\/41919117\/oncolo_24_11_e1123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/11\/e1123\/41919117\/oncolo_24_11_e1123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:05:51Z","timestamp":1640419551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/11\/e1123\/6439860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,4,5]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0789","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,4,5]]}}}